JEAN‑PIERRE WYSS

Jean-Pierre Wyss serves as a highly respected Partner at Gilde Healthcare, a prominent European venture capital and growth equity firm dedicated to the healthcare sector. In his role, Jean-Pierre is instrumental in driving Gilde Healthcare's investment activities, particularly within the dynamic fields of medical technology (MedTech), digital health, and diagnostics. He is actively involved in all stages of the investment process, from initial deal sourcing and rigorous due diligence to strategic portfolio management and successful exits.

His investment philosophy centers on identifying companies that possess groundbreaking innovation, strong intellectual property, and robust management teams capable of executing ambitious growth strategies. Jean-Pierre seeks out opportunities that address significant unmet medical needs or offer substantial improvements to existing healthcare solutions, ultimately aiming to deliver both financial returns and positive patient impact. His expertise spans a wide range of sub-sectors, including medical devices, health IT platforms, diagnostic tools, and digital therapeutics.

Prior to joining Gilde Healthcare in 2008, Jean-Pierre built an impressive career foundation in both industry and consulting. He spent several years at Roche Diagnostics, a global leader in in-vitro diagnostics, where he held various key management positions across marketing, sales, and business development. His tenure at Roche provided him with deep operational insights and a comprehensive understanding of the global healthcare market, particularly in Europe and the United States. Before his time at Roche, Jean-Pierre honed his strategic and analytical skills as a consultant at Accenture, formerly Andersen Consulting, advising clients across diverse industries. Academically, he holds an MBA from INSEAD and a Master's degree in Biomedical Engineering from ETH Zurich, further solidifying his blend of business acumen and scientific understanding.

Throughout his career at Gilde Healthcare, Jean-Pierre has been involved in numerous successful investments and exits, contributing significantly to the growth and innovation within the healthcare landscape. Notable investments where he has played a key role include Miracor Medical, Lumeon, Exo Imaging, and Mevion Medical Systems. He also contributed to successful exits such as StatDx (acquired by QIAGEN), Respicardia (acquired by Zoll Medical), Invision (acquired by Exact Sciences), NightBalance (acquired by Philips), and Sapiens Steering Brain Stimulation (acquired by Medtronic), demonstrating his ability to identify and scale promising ventures.